Personalized representation from a leader in precision medicine and biologics patent law
Amelia Feulner Baur’s practice covers a broad spectrum of intellectual property issues, including patent preparation and prosecution, coordination of worldwide patent strategies, appeals to the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office and the Court of Appeals for the Federal Circuit (CAFC). Amelia has been recognized as an IP Star by both Managing Intellectual Property and LMG Life Sciences.
She has extensive experience working with clients to develop effective patent strategies to meet business goals. This includes landscape analyses, due diligence investigations, and providing patentability, freedom-to-operate, infringement, and validity opinions. In addition, Amelia has led clients through inter partes review (IPR), reexaminations, interferences, and the settlement of patent disputes. She has worked with biotech startups, research foundations, and larger, established pharmaceutical companies.
Amelia earned her PhD degree in molecular microbiology, where she gained extensive hands-on experience in the fields of microbiology, immunology, biochemistry, molecular biology, and infectious disease. She has substantial legal experience in many biotechnology and pharmaceutical practice areas including antibodies and antibody variants, diagnostic and detection methods, protein purification, vaccine technology, fusion proteins, gene cloning and expression, and gene and protein mutations.
Prior to founding McNeill Baur PLLC, Amelia spent more than a decade at two large IP firms: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP and Nixon Peabody, LLP.
She is married to Dr. Joseph Baur, Associate Professor in the Department of Physiology and Institute for Diabetes, Obesity and Metabolism, at Perelman School of Medicine at the University of Pennsylvania.
“Navigating through the Obviousness-Type Double Patenting Minefield,” Landslide 10 (3), January/February 2018 (coauthor).
“Navigating the Limitations on Discovery in AIA Post-Grant Proceedings,” Buffalo Intellectual Property Law Journal, December 3, 2015 (coauthor).
“US Supreme Court Provides New Hurdles for Personalized Medicine in Limelight Networks v. Akamai Technologies” Bloomberg BNA, World Intellectual Property Report, September 2014
“Comments of the American Bar Association Section of Intellectual Property in Response to the USPTO’s Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Laws of Nature, Natural Phenomena & Natural Products,” July 30, 2014 (coauthor).
“Ask The Expert: Are Diagnostic Patents Dead?,” Clinical Laboratory News 40(7):44 (2014).
“Personalized Medicine Patents at Risk: Tips for Battling Prometheus and Myriad to Obtain Claims to Diagnostics,” CIPA Journal, March 2013 (coauthor).
“Patenting Personalized Medicine,” The Journal of Biolaw and Business, 2006 (coauthor).
“Creating and Enforcing Patent Rights in the Fast Moving Field of Personalized Medicine,” The Journal of Biolaw and Business, 2006 (coauthor).
“Identification of Acyloxyacyl Hydrolase, a LipopolySaccharide-Detoxifying Enzyme, in the Murine Urinary Tract,” Infection and Immunity, June 2004 (coauthor).